Stock Ratings / Health Care / SNY / earnings

GSK (57) BMY (63) REGN (80) VRTX (80) ⌘ Pro Terminal →

Sanofi ADS (SNY) Next Earnings Date & Expected ±3.8% Move

$44.34 +2.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $44.48

Sanofi ADS (SNY) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $105.19B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SNY Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Sanofi ADS (NASDAQ: SNY) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $44.34 (+2.81% 1D, market cap $105.19B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, SNY ranks #178 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SNY compare to GSK and BMY in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNY carries a Roarable C- (59/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, GSK (GSK plc American) holds a D+ grade (57/100 RQD, P/E 32.8x, ROIC 9.9%, cap $98.47B) and BMY (Bristol-Myers Squibb Company) posts a C grade (63/100 RQD, P/E 17.8x, ROIC 13.3%, cap $125.40B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SNY?

▼

For Sanofi ADS (SNY), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #178 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $44.48 (+0.32%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 15.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNY)Realized 20D OHLCV Swing Band: ±3.8%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY SNY SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (27% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (20% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy • Cannibal Buyback (-1.24% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (58.8) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$39.12+5.8% Next Q

Q2 (-2Q)

Grade C-$41.40+1.2% Next Q

Q3 (-1Q)

Grade C$41.89+5.8% Next Q

Current

Grade C-$44.34+0.2% Hist 90D α

Trajectory: C- (51) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the SNY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, SNY faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($42.10) or 200D SMA ($44.29) invalidates the momentum regime and cuts Target Base ($44.54) toward Bear Floor ($34.74).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SNY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±3.8% Swing Band

±$1.68 Expected Swing

MODEL EARNINGS SETUP GAUGE

SNY Quantitative Pre-Earnings Setup: 59/100

Trailing EPS: $1.31 • YoY Revenue Growth: -1.1%

Model Bullish Setup (59/100)Model Risk Weight (41/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating SNY & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on SNY
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SNY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.28%▼ DESCENDING CHANNEL

2026-11-02O $42.24H $44.34L $42.24C $44.34VOL 4.27M

RES: $45.27SUP: $38.72SMA50: $42.10SMA200: $44.29

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNY Butterfly Map → + Track SNY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

25.3%/yr Implied 5Y Growth

vs. -1.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SNY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNY)

Health Care Rank #178 of 1016 ⚔️ GSK vs SNY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNY vs. GSK, BMY, REGN, VRTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sanofi ADS (SNY) ranks #178 by composite RQD confidence (59/100, grade C-) and #22 by equity capitalization ($105.19B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. REGN currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with SNY at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SNY ACTIVE Sanofi ADS	C-	59/100	32.8x	—	9.9%	+2.81%	$105.19B	Benchmark Subject
GSK GSK plc American	D+	57/100	32.8x	—	9.9%	+1.71%	$98.47B	/gsk-vs-sny →
BMY Bristol-Myers Squibb Company	C	63/100	17.8x	71.1%	13.3%	+1.78%	$125.40B	/bmy-vs-sny →
REGN Regeneron Pharmaceuticals Inc.	B+	80/100	18.7x	—	9.4%	+13.33%	$84.30B	/regn-vs-sny →
VRTX Vertex Pharmaceuticals Incorporated	B+	80/100	34.6x	86.2%	20.0%	+3.50%	$136.87B	/vrtx-vs-sny →

2. SNY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Sanofi ADS (SNY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $105.19B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 7/9.

3. SNY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SNY compare to GSK and BMY in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SNY?

Where is SNY trading relative to its 50-day, 200-day, and 52-week technical levels?

SNY last traded at $44.34 (+2.81% on volume of 15,101,933 shares), positioning the stock +5.32% above its 50-day simple moving average ($42.10) and +0.11% above its 200-day simple moving average ($44.29). Across its 52-week range of $39.07 to $52.68, SNY sits at the 38.7% percentile with a 14-day RSI of 58.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±3.8% ($42.66 to $46.02).

SNY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is SNY's next earnings date?

Based on SEC filing cadence, Sanofi ADS (SNY)'s next quarterly reporting window is estimated around Upcoming Quarter.

How much is SNY stock expected to move on earnings?

Volatility modeling currently projects a ±3.8% event move for SNY, spanning a range between $42.66 and $46.02.

Direct Sub-Reports: SNY RQD Cockpit SNY 12M Forecast SNY Earnings & Move SNY Dividends & DRIP SNY Insiders & 13F SNY Whale Options SNY Profit Sankey SNY News & Why

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SNY — Sanofi ADS: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:08:13Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SNY scores 59 out of 100, which corresponds to a letter grade of C- and a verdict label of "Roarable Hold — Cautious Neutral." The five pillars are:

Fundamental Cash Engine: 11 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 9.9% and an FCF yield of 2.21%. These are the two cash-generation measures that most directly test whether the business earns more than its cost of capital and returns cash to owners. A moderate ROIC paired with a low FCF yield suggests the stock is priced richly relative to current cash generation, so upside would depend on earnings growth rather than yield support.
Whale / 13F Flow: 11 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. The score is mid-range, indicating neither strong institutional conviction nor clear distribution. Source detail on holdings is not available in source data.
Insider Conviction: 12 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The score is modestly above midpoint. Transaction-level detail is not available in source data.
Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, this pillar reflects beta of 1.14 and sector sensitivity. This is the weakest pillar. A beta above 1.0 means the stock has historically moved somewhat more than the broad market, so it may amplify drawdowns in a risk-off regime while offering less defensive protection than a low-beta holding.
Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, this pillar reflects Altman Z 3.74, Piotroski F 7/9, and Debt/Equity 0.39. This is the strongest pillar and indicates a financially sound balance sheet with low leverage and solid accounting-quality signals.

Taken together, the investor implication is that balance-sheet strength provides a floor on downside risk, while valuation (P/E TTM 32.8, EV/EBITDA 21) and a weak macro-fit score temper upside. Upside drivers would be earnings growth that compresses the multiple; valuation tradeoffs center on paying a premium for current earnings with a modest FCF yield. This is an analytical framework, not personalized advice.

Snapshot

Price	Market Cap	P/E (TTM)	Forward P/E	EV/EBITDA	EPS (TTM)	Dividend Yield	Beta	52-Wk Range	ROIC %
43.13	$105.19B	32.8	30.5	21	1.31	0%	1.14	$39.07 - $52.68	9.9%

Business

Sanofi ADS (SNY) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the company profile, it carries a market capitalization of $105.2B. Not available in source data: product lines, customer segments, and revenue model detail.

Recent Catalysts & News Wire Analysis

Earnings (GREEN, CATALYST): A headline cites Q2 2026 EPS beating consensus by 8.91% while shares slipped, alongside a guidance-downgrade alert. The two signals conflict and the source does not resolve the guidance detail.
Market wire (YELLOW): A related-symbol item for QPOWER.NS is linked to SNY in the feed but concerns an unrelated Indian electrical equipment issuer; it carries no direct SNY signal.
Market wire (YELLOW): A related-symbol item for Fusemachines warrants (FUSEW) is similarly unrelated to SNY and reflects retail-driven sub-penny trading in a different security.

Risk watch: the guidance-downgrade alert is the most material item to monitor. Proprietary signals: none. Butterfly graph shows no supply-chain links.

Open Questions

What did the Q2 2026 guidance change actually entail, given the EPS beat and the downgrade alert appear together?
What are the revenue, operating income, and cash flow figures by period, since the financials section is empty?
Which institutions hold SNY and how have 13F positions trended?
Does the gross margin of 0% reflect a data gap or a true reporting issue?
What drives the 32.8 trailing P/E relative to the 1.31 EPS, and how sustainable is the growth implied by the forward P/E of 30.5?

SNY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sanofi ADS (SNY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SNY Debate Forum (3) ↓

🟢 CATALYST https://www.dars.gov.et/ • 9h ago

SNY Q2 2026 Earnings: EPS Beats Consensus by 8.91% Even as Shares Slip - Guidance Downgrade Alert

https://www.dars.gov.et/ report covering Sanofi ADS (SNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 12h ago

QPOWER.NS Slips 3.25% to ₹1,407.10: Quality Power Electrical Equipments Tests Key Support Zone - Social Sentiment

https://www.siam.in/ report covering Sanofi ADS (SNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.dars.gov.et/ • 15h ago

Fusemachines Warrants (FUSEW) Slide 12.28% to $0.01 as Sub-Penny Trading Dominates - Retail Driven Moves

https://www.dars.gov.et/ report covering Sanofi ADS (SNY) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 1d ago

Sanofi (ENXTPA:SAN) Stock Can Q3 Earnings Sustain Its Revenue Strength

Sanofi walked into its Q3 2026 report with the share price at €79.74 after a solid run over the past month, and the mood already leaning optimistic. The headline was clear: quarterly revenue landed at €15.2b and basic ea

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 2d ago

Regeneron: 3 Key Takeaways for Long-Term Investors

An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.

Read Full Source ↗

🟢 CATALYST Yahoo • 2d ago

Regeneron Stock Just Hit a 2-Year High. Here's Why.

Regeneron rallied to a two-year high as Dupixent drives strong Q3 earnings. But is there any further upside left in REGN shares? Let’s find out!

Read Full Source ↗

🟢 CATALYST Yahoo • 2d ago

Regeneron (REGN) stock trades up, here is why

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-quarter 2026 revenue to $5.1 billion, alongside a 70% rise in non-GAAP diluted ea

Read Full Source ↗

🟢 CATALYST Yahoo • 3d ago

EssilorLuxottica Stock And Eurozone Healthcare Giants Worth Watching Now

Eurozone growth just cooled to 0.4% in Q3, yet still beat forecasts, and that mix of resilience and slowdown is quietly reshaping where money could flow next. Some businesses may benefit if investors rethink how far the

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SNY Bull vs. Bear Conversation Board — What's Your Call at $44.34?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNY 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $46.58 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SNY (C- • RQD 59/100) a Buy at $43.13?

Welcome to the SNY (Sanofi ADS) Roar Pit. Current RQD Composite is 59/100 (Roarable Hold — Cautious Neutral) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $32.78 (-24.0%)

Spot @ $43.13

Pump the brakes on SNY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SNY, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless Sanofi ADS expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $52.62 (+22.0%)

Spot @ $43.13

SNY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SNY, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $43.13 (52-wk range $39.07 - $52.68), any beat on forward guidance forces shorts and underweight funds to chase.